Protein Expression News and Research

RSS

Sciatic nerve injury can cause differential expression of microRNAs in dorsal root ganglia

Slit-Robo GTPase-activating protein 3 contains a Rho GAP domain that regulates the activities of Rho family GTPases and affects actin polymerization, which influences dendrite elaboration, neurite outgrowth and axon guidance, contributing to neural regeneration.

21 Jul 2014

Moxibustion and electroacupuncture alleviate neuronal cytoplasmic edema in AD

Aberrant Wnt signaling is possibly related to the pathological changes in Alzheimer's disease (AD). Axin and β-catenin protein is closely related to Wnt signaling.

18 Jul 2014

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report.

16 Jul 2014

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations.

16 Jul 2014

Researchers discover a way to restore corneal surface

A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye.

3 Jul 2014

Research provides unique insight into lncRNAs that regulate lung development

It's a long way from DNA to RNA to protein, and only about two percent of a person's genome is eventually converted into proteins.

19 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

New study redefines gene responses to external stimulus

An international team led by scientists at the University of Turku in Finland studied thermally-adapted fish populations to discover that the more biological functions a gene has, the less it responds to environmental change. "In addition to having important implications for climate change adaptation, these findings could radically change the way we study gene responses to any external stimulus like for example to drug treatments", the authors suggest.

5 Jun 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Shuganjieyu capsule reverses depressive behaviors by increasing brain-derived neurotrophic factor

Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Administration of China since 2008.

8 May 2014

Study focuses on mutated protein associated with early onset torsion dystonia

A collaborative discovery involving Kansas State University researchers may lead to the first universal treatment for dystonia, a neurological disorder that affects nearly half a million Americans.

7 May 2014

Study reveals how ovarian cancer metabolism changes between early, late stages

A Rice University-led analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize, or spread to other parts of the body. The study also suggests how ovarian cancer treatments can be tailored based on the metabolic profile of a particular tumor.

6 May 2014

Researchers discover potential genetic variant that may make brains more resilient against Alzheimer's

Autopsies have revealed that some individuals develop the cellular changes indicative of Alzheimer's disease without ever showing clinical symptoms in their lifetime.

5 May 2014

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

10 Apr 2014

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

An international research group led by Arizona State University professor Qiang "Shawn" Chen has developed a new generation of potentially safer and more cost-effective therapeutics against West Nile virus and other pathogens.

29 Mar 2014

The Center for Applied Nanotechnology presents a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays

The nano-experts from the Center for Applied Nanotechnology (CAN) GmbH expand their product portfolio by CANdots® Series G - His Detect, which is a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays. It is easy to handle, highly sensitive as well as time saving compared to standard methods available on the market, e.g. ECL.

25 Mar 2014

Researchers uncover cause of rare type of ovarian cancer that strikes girls and young women

The cause of a rare type of ovarian cancer that most often strikes girls and young women has been uncovered by an international research team led by the Translational Genomics Research Institute, according to a study published online today by the renowned scientific journal, Nature Genetics.

23 Mar 2014